Abstract:Abstract BACKGROUND: Chemotherapy resistance is recognized to occur not only through selection of pre-existing genetically resistant clones, but also through rapid phenotypic plasticity mechanisms. We previously reported that bladder cancer cells can rapidly transition to and from a chemo-resistant phenotype. Recently, N6-methyladenosine (m6A) RNA modifications were shown to dynamically and reversibly regulate mRNA processing, differentiation, and cell fate. Here, we tested the hypothesis that m6A modifications regulate phenotypic plasticity and transition to cisplatin resistance in bladder cancer (BC). METHODS: We utilized methyl-RNA-immunoprecipitation followed by sequencing (MeRIP-seq) and by RNA-seq to identify transcripts that were both differentially methylated and differentially expressed between cisplatin-sensitive and cisplatin-resistant BC cell lines. Candidate transcripts were annotated using Gene Ontology (GO) enrichment analysis and Gene Set Enrichment Analysis (GSEA). Clinical relevance was evaluated using databases such as The Cancer Genome Atlas (TCGA) and the Oncology Research Information Network (ORIEN) avatar. Cancer-relevant genes were then validated in vitro by targeted immunoprecipitation and PCR (MeRIP-PCR) and qPCR. Candidate genes were then functionally validated in cell lines and in patient derived organoids (PDOs) by siRNA-mediated knockdown and cisplatin treatment, as well as by m6A measurement after short-term cisplatin treatment. RESULTS: MeRIP-seq and RNA-seq revealed that cisplatin-sensitive and cisplatin-resistant BC cells have distinct m6A profiles, with 130 transcripts that were both differentially methylated and differentially expressed. Using clinical and functional database tools, we filtered this list to 37 transcripts and ranked them based on clinical relevance in BC. Of the top 15 candidates, eight were successfully validated in vitro via repeat qPCR and MeRIP-PCR. In cisplatin-resistant cells, one candidate, SLC7A11, was found to have decreased m6A level, which was associated with increased RNA stability and elevated transcript and protein levels. Consistent with this, 48 hr cisplatin treatment of cisplatin-sensitive cells led to SLC7A11 hypomethylation, increased RNA stability, and elevated transcript and protein levels. Furthermore, depletion of SLC7A11 by siRNA-knockdown re-sensitized BC cell lines and PDOs to cisplatin. CONCLUSIONS: Using unbiased transcriptome-wide m6A profiling followed by targeted validation, we demonstrated that m6A modifications regulate expression of clinically relevant gene transcripts in BC, and that a subset of these modifications may promote resistance to chemotherapy Collectively, these results implicate epitranscriptomic plasticity as a driver in potentiating cisplatin resistance in bladder cancer. Citation Format: Emmanuelle Hodara, Aubree Mades, Tong Xu, Amir Goldkorn, Suhn Rhie. M6A RNA modifications regulate expression of transcripts that promote transition to cisplatin resistance in bladder cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3908.

Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism

N6-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges

Recent Advances in the Contribution of Noncoding RNAs to Cisplatin Resistance in Cervical Cancer

Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies

Abstract 3908: M6A RNA modifications regulate expression of transcripts that promote transition to cisplatin resistance in bladder cancer

Comprehensive Analysis of Circular RNA Expression Profiles in Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines

LncRNA-MALAT1 Mediates Cisplatin Resistance Via Mir-101-3p/vegf-c Pathway in Bladder Cancer.

The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer

Long Non-Coding RNA UCA1 Promotes Cisplatin/gemcitabine Resistance Through CREB Modulating Mir-196A-5p in Bladder Cancer Cells.

The Role of Non-Coding RNAs in Breast Cancer Drug Resistance

Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models

Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors

Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p

CAB39 Promotes Cisplatin Resistance in Bladder Cancer Via the LKB1-AMPK-LC3 Pathway.

Targeting ERCC2 with Sirna Self-Assembled Nanoparticles to Enhance the Cisplatin Response in Bladder Cancer

MicroRNA-146b-5p/FDFT1 Mediates Cisplatin Sensitivity in Bladder Cancer by Redirecting Cholesterol Biosynthesis to the Non-Sterol Branch

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers

m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer

Single-cell Transcriptome Analysis Reveals the Association between Histone Lactylation and Cisplatin Resistance in Bladder Cancer

Long Non‐coding RNA UCA1 Increases Chemoresistance of Bladder Cancer Cells by Regulating Wnt Signaling

Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment